This panel features four speakers and a moderator focusing on understanding how family offices view direct investments in early-stage healthcare opportunities (seed – series A) and how the differ/compare to VCs. Topics may include:
- Primary differences between institutional VCs and family office investors
- How family offices source investments / how to get on their radar
- Trends in the early-stage healthcare investment space
The primary goal of this panel is to help entrepreneurs understand how family offices view early-stage investments in the healthcare space and best practices for approaching, pitching and working with these groups as well as debunking some common misconceptions about family offices.
Colin Widen, CEO, Boston Innovation Capital
Colin Widen, registered representative, is a seasoned executive with 25 years of sales, trading and portfolio management experience in major investment banks. In 2001, Colin left the institutional world and founded W.A.M. Asset Management, a private equity fund of funds that focused on SBIC private equity funds. After selling the firm to a larger fund of funds, Colin joined Deutsche Bank where he led a team providing consulting services about alternative asset allocation strategies to family offices and smaller endowments and foundations. Colin is a registered representative and holds Series 7, 24, 63 and 82 registrations. His specialties include reconstructing hedge fund portfolios and analyzing private equity holdings.
Eugene Durenard, Managing Director, Stetson Family Office
Eugene brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years. He started his career in London in proprietary research at Salomon Brothers, then proprietary trading at Credit Suisse. He founded Orion Investment Management, an asset manager in Bermuda that he sold to the privately owned Capital G Bank, and co-headed their asset management. Prior to joining the Stetson Family Office he was CIO of another family office operation in NYC. Eugene published several innovations to trading and dynamic asset management in several industry articles and a book “Professional Automated Trading, Theory and Practice” (Wiley 2013). He holds a PhD in Mathematics from Harvard.
Ron Paliwoda, Founder & President, Paliwoda Group
Ron Paliwoda is an accidental entrepreneur and seasoned investor, primarily through the Ventures arm of The Paliwoda Group, the firm he founded over 20 years ago. The firm’s evergreen Health Tech Fund targets early-stage innovation that reduces costs to healthcare consumers, including projects that promote cost transparency to help consumers make more informed decisions in selecting service providers; that weave raw data streaming from remote patient monitors into insight about one’s health and fitness (i.e. BioArray); and innovations at the intersection of molecular diagnostics and computational biology that use machine-learning tools to better understand complex disorders (i.e. Genotype Diagnostics). Ron actively advises entrepreneur leaders working to solve care and education challenges at underserved communities, and is a passionate advocate of local working environments where startups are nurtured and high-potential teams can excel.
Sherry Grisewood, Chief Investment Officer, FoxHill Asset Management
“Sherry has extensive Wall Street professional experience in banking, corporate advisory and research capacities primarily for early stage life science and related technology companies with particular focus in therapeutic areas where there is an intersection of technologies.
Sherry currently chairs the Audit Committee and is a member of the Compensation Committee for Tapimmune, Inc., and sits on the Board of Oncolix, Inc., both public companies, and Mobitech Regenerative Medicine, Inc., a private orthopedics device company. Sherry holds FINRA general securities, investment banking and research principals licenses, is a member of the CFA Institute, TERMIS, ASGCT, Women in Bio and the Jazz Society of New Jersey.”
Kevin Schimelfenig, Managing Partner, McGeever
Kevin Schimelfenig is the Founder and Managing Partner of McGeever, LLC, a family office positioned to establish, administer and govern the financial and philanthropic values and goals of the family. McGeever’s investment portfolio includes but is not limited to; Healthcare, Real Estate, Energy, and Information Technology. Through McGeever, Kevin participates in investments with multiple Angel Funds and is a limited partner with Private Equity firms on the East and West Coast as well as has affiliations with well-known medical device and diagnostic institutions across the United States. In addition, Kevin is acting President and CEO of SalesForce4Hire, McGeever LLC’s wholly owned subsidiary. SalesForce4Hire partners with medical device, diagnostic, pharma/biotech and information technology companies and their investors to provide strategic models and solutions for commercialization. Kevin’s educational background includes a B.S. in Business Administration from Marywood University and extensive training in the Diabetes Program at Konkuk University Hospital in Seoul, South Korea. Kevin was recognized as a North Carolina top 50 Entrepreneur and has been an invited speaker for prominent organizations across the nation including JPMorgan/OneMedForum, AdvaMed, and Angel Capital Association. Kevin has served on multiple boards and currently serves on the Board of Directors for Physcient, Inc., and Akros Medical.